keyword
MENU ▼
Read by QxMD icon Read
search

carboplatin hypersensitivity reaction

keyword
https://www.readbyqxmd.com/read/29435291/efficacy-and-safety-of-doceaqualip-in-a-patient-with-locally-advanced-cervical-cancer-a-case-report
#1
Rammohan Prasanna, Deepak Bunger, Mujtaba A Khan
The standard of care for locally advanced cervical cancer has been the combination of a taxane with platinum based therapy. Conventional docetaxel is known to cause hypersensitivity reactions, fluid retention and other toxicities due to polysorbate-80 and ethanol. Corticosteroid premedication prior to docetaxel administration is required to prevent these toxicities, however, toxicities are still observed, sometimes fatal, despite premedication. DoceAqualip, a nanosomal docetaxel lipid suspension, developed with lipids generally regarded as safe (GRAS) by the US Food and Drug Administration, is devoid of polysorbate-80 and ethanol...
February 2018: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/29361624/-safety-and-efficacy-of-cisplatin-treatment-after-carboplatin-hypersensitivity-reactions-in-gynecologic-malignancies
#2
Naoki Matsuoka, Takanori Yokoyama, Etsuko Fujimoto, Mika Sakai, Shinichi Okame, Yuko Shiroyama, Takashi Yokoyama, Kazuhiro Takehara
To investigate the safety and efficacy of cisplatin(CDDP)treatment after carboplatin(CBDCA)hypersensitivity reactions (CHSR)in gynecologic malignancies, we retrospectively reviewed the clinical records of 544 patients who underwent paclitaxel and CBDCA therapy(TC therapy). CHSR was observed in 18 patients. Eight patients were administered weekly paclitaxel and CDDP therapy(wTP therapy)continuously, to confirm that there was no CDDP hypersensitivity followingintravenous administration of 10 mgCDDP. At the onset of CHSR, the patients had received a median of 9 TC therapy cycles, and the median number of CBDCA administrations was 14...
December 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/29361511/outcome-of-490-desensitizations-to-chemotherapy-drugs-with-a-rapid-one-solution-protocol
#3
Eva Pérez-Rodríguez, Juan Antonio Martínez-Tadeo, Natalia Pérez-Rodríguez, Guacimara Hernández-Santana, Ariel Callero-Viera, Elena Rodríguez-Plata, José Carlos García-Robaina
BACKGROUND: Hypersensitivity reactions to chemotherapy drugs are quite frequent. Desensitization for chemotherapy drugs has become an option to maintain first-line therapy in patients who have suffered such reactions. OBJECTIVE: The objective of this study was to describe our experience in desensitization with antineoplastic agents using a rapid 1-solution protocol. METHODS: We performed a 3-year prospective observational study recording all patients who were desensitized with this protocol...
January 17, 2018: Journal of Allergy and Clinical Immunology in Practice
https://www.readbyqxmd.com/read/29208369/prophylactic-3-hour-graduated-infusion-schedule-minimizes-risk-of-carboplatin-hypersensitivity-reactions-a-prospective-study
#4
Anjila Koul, Eva L Forsland, Maria Bjurberg
OBJECTIVE: Aim of this study was observation of hypersensitivity reaction (HSR) frequency by using a 3-hour graduated infusion protocol with appropriate premedication as a prophylactic measure in patients with gynecological cancer receiving carboplatin retreatment in second line or above. None of the patients had experienced HSRs to platinum previously. METHOD: All the patients in this study received premedication with corticosteroids and anti-histamines followed by carboplatin as 3-hour graduated infusion...
February 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29163536/drug-hypersensitivity-and-anaphylaxis-in-cancer-and-chronic-inflammatory-diseases-the-role-of-desensitizations
#5
REVIEW
Mariana Castells
Drug allergy is a rising problem in the twenty-first century which affects all populations and races, children, and adults, and for which the recognition, diagnosis, management, and treatment is still not well standardized. Classical and new chemotherapy drugs, monoclonal antibodies (MoAbs), and small molecules to treat cancer and chronic inflammatory diseases are aimed at improving quality of life and life expectancy of patients, but an increasing number of reactions including anaphylaxis precludes their use in targeted populations...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/29163180/risk-factors-of-hypersensitivity-to-carboplatin-in-patients-with-gynecologic-malignancies
#6
Yu-Hsiao Tai, Yi-Jou Tai, Heng-Cheng Hsu, Shu-Ping Lee, Yun-Yuan Chen, Ying-Cheng Chiang, Yu-Li Chen, Chi-An Chen, Wen-Fang Cheng
We evaluated the prevalence of and risk factors for hypersensitivity reactions related to carboplatin, which is commonly used to treat gynecological malignancies. All women with pathologically documented ovarian, fallopian tube, or primary peritoneal cancer treated with carboplatin alone or a carboplatin-based combination chemotherapy regimen at a single hospital between January 2006 and December 2013 were retrospectively recruited. We analyzed the incidence, characteristics, risk factors, management, and outcomes of carboplatin-related hypersensitivity reactions among these patients...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28965633/platinum-chemotherapy-hypersensitivity-prevalence-and-management
#7
REVIEW
Iris M Otani, Johnson Wong, Aleena Banerji
Hypersensitivity reactions to platinum agents are common. For carboplatin and cisplatin, the first hypersensitivity reaction typically occurs around the second and third re-exposure during the second line of therapy (eighth and ninth courses overall). For oxaliplatin, the first hypersensitivity reaction can occur throughout the treatment course. Skin testing helps risk stratify patients to appropriate desensitization protocols and assess risk for breakthrough HSRs during desensitization. A risk-stratification protocol using 3 serial skin tests and desensitization protocols enables patients with platinum agent hypersensitivity to receive first-line chemotherapy treatment safely...
November 2017: Immunology and Allergy Clinics of North America
https://www.readbyqxmd.com/read/28911062/tpf-plus-cetuximab-induction-chemotherapy-followed-by-biochemoradiation-with-weekly-cetuximab-plus-weekly-cisplatin-or-carboplatin-a-randomized-phase-ii-eortc-trial
#8
P M Specenier, E Remenar, J Buter, D L Schrijvers, C Bergamini, L F Licitra, A Awada, P M Clement, C Fortpied, J Menis, J B Vermorken
Background: Our aim was to test the safety of cetuximab added to chemoradiation with either cisplatin or carboplatin after prior induction chemotherapy. Methods: Patients with stage III/IV unresectable, squamous cell carcinoma of the head and neck received up to four cycles of TPF-E (cisplatin and docetaxel 75 mg/m2 on day 1 followed by 5-FU 750 mg/m2/day as a continuous infusion on days 1-5 plus cetuximab at a loading dose of 400 mg/m2 followed by a weekly dose of 250 mg/m2), with prophylactic antibiotics but no growth factors...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28664179/the-tell-tale-heart-a-case-of-recurrent-vulvar-carcinoma-with-cardiac-metastasis-and-review-of-literature
#9
Syed Imran Mustafa Jafri, Naveed Ali, Salman Farhat, Faizan Malik, Mark Shahin
A 50-year-old female was diagnosed with vulvar cancer treated with left partial vulvectomy and bilateral lymphadenectomy. Ten months after her surgery, she presented with increased labial swelling, pain and discharge. Biopsy confirmed recurrence of squamous cell vulvar carcinoma. Incidentally, on restaging radiographic scans, she was found to have a large right ventricular mass which, after surgical debulking, was shown to be a squamous cell cancer of vulvar origin. She was commenced on chemotherapy with carboplatin and paclitaxel along with concurrent radiation therapy...
August 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28622171/reactions-to-cytostatic-agents-in-children
#10
Josefina R Cernadas
PURPOSE OF REVIEW: The current review will focus on drug hypersensitivity reactions to chemotherapy specifically to those drugs most used in children. We know that potentially all chemotherapeutic agents can cause infusion reactions, generally defined as adverse drug reactions. Of these, some are Type A, defined as expected and described in the characteristics of the drug and others, and Type B, defined as unexpected reactions which cannot be explained by the known toxicity profile of the drug...
August 2017: Current Opinion in Allergy and Clinical Immunology
https://www.readbyqxmd.com/read/28541630/universal-tolerance-of-nab-paclitaxel-for-gynecologic-malignancies-in-patients-with-prior-taxane-hypersensitivity-reactions
#11
Kathryn Maurer, Chad Michener, Haider Mahdi, Peter G Rose
OBJECTIVE: To report on the incidence of nab-paclitaxel hypersensitivity reactions (HSRs) in patients with prior taxane HSR. METHODS: From 2005 to 2015, all patients who received nab-paclitaxel for a gynecologic malignancy were identified. Chart abstraction included pathology, prior therapy, indication for nab-paclitaxel, dosing, response, toxicities including any HSR, and reason for discontinuation of nab-paclitaxel therapy. RESULTS: We identified 37 patients with gynecologic malignancies with a history of paclitaxel HSR who received nab-paclitaxel...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28446876/hypersensitivity-to-carboplatin-in-children-with-malignancy
#12
REVIEW
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Giorgio Attinà, Riccardo Riccardi
Purpose: Carboplatin-based regimens have proven efficacy in children with cancer. However, the development of hypersensitivity reactions (HSRs) may have a negative impact on treatment intensity and patients' outcome. The aim of this review is to summarize the incidence and the clinical features of HSRs occurring in children with cancer treated with carboplatin and their impact on treatment efficacy. Methods: Data were collected by searching for relevant studies on the incidence, clinical features and management of possible side effects about the use of carboplatin in children, published from March 1987 to October 2016 in the PubMed database...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28439238/rechallenge-to-carboplatin-in-children-with-low-grade-glioma-and-carboplatin-hypersensitivity-reactions
#13
Antonio Ruggiero, Daniela Rizzo, Martina Catalano, Palma Maurizi, Stefano Mastrangelo, Giorgio Attinà, Riccardo Riccardi
Background: Carboplatin based regimens have demonstrated activity in pediatric patients with low grade gliomas (LGG). However, carboplatin hypersensitivity reactions (CHRs) may be a major problem leading to premature cessation of an effective therapy. The objectives of this study were to describe the prevalence, characteristics and management of CHR. Methods: We performed a retrospective review of children with LGG treated between January 1994 and July 2015 with carboplatin and vincristine who had a documented CHR...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28345825/comparison-of-hypersensitivity-reactions-to-carboplatin-retreatment-in-gynecologic-cancer-patients-between-one-and-two-hour-infusions-a-randomized-trial-study
#14
Weerawich Pornwattanakrilert, Prapaporn Suprasert
Objective: To compare the incidence rate of carboplatin hypersensitivity reactions (HSRs) in gynecologic cancer patients receiving one-hour or two-hour carboplatin retreatment infusions. Setting: A Prospective Randomized Controlled Trial. Methods: Recurrent gynecologic cancer patients 25 to 80-years of age who were scheduled to receive carboplatin retreatment after previously receiving at least six cycles of carboplatin without a history of platinum allergy were invited to enroll. They were randomized to receive either a one-hour or two-hour carboplatin infusion in each cycle...
February 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28124284/incidence-of-and-risk-factors-associated-with-nedaplatin-related-hypersensitivity-reactions
#15
Yuki Kawarada, Masayuki Miyazaki, Ayaka Itoh, Risa Araki, Hidetaka Iwamizu, Tomomi Kataoka, Yasuo Kumakura, Akiko Ota, Taku Nagai, Kiyofumi Yamada
BACKGROUND: Nedaplatin (NDP)-related hypersensitivity reactions (HSRs) trigger adverse clinical events. Prediction and prevention of NDP-HSRs are thus essential to minimize the risk and maximize the benefit of NDP therapy. However, the incidence of NDP-HSRs and the associated risk factors remain unclear. METHODS: We retrospectively examined patients who received NDP monotherapy between April 2011 and July 2015 in Nagoya University Hospital. HSRs severity was defined according to the Common Terminology Criteria for Adverse Events version 4 (CTCAE ver...
June 2017: International Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28094039/cisplatin-can-be-safely-administered-to-ovarian-cancer-patients-with-hypersensitivity-to-carboplatin
#16
A Bergamini, C Pisano, M Di Napoli, L Arenare, C Della Pepa, R Tambaro, G Facchini, P Gargiulo, S Rossetti, G Mangili, S Pignata, S C Cecere
OBJECTIVE: Hypersensitivity reactions (HSR) are frequently reported in patients rechallenged with carboplatin for recurrent ovarian cancer (ROC) and represent a critical issue, since discontinuation of the platinum-based therapy could affect prognosis. Several strategies to allow platinum rechallenge have been described, with controversial outcomes. The aim of this study is to illustrate a 10-year experience with cisplatin in patients with a previous HSR to carboplatin or at risk for allergy...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27916065/-clinical-analysis-of-hypersensitivity-reaction-of-platinum-in-ovarian-cancer-and-cervical-cancer-patients
#17
L Li, M Wu, J X Yang, X R Wan, H F Huang, L Y Pan, K Shen, J H Lang, Y Xiang
Objective: To investigate the incidence, risk factors, management and prognosis of hypersensitivity reaction (HSR) of platinum-based chemotherapy in patients of ovarian cancer and cervical cancer. Methods: Cases from Peking Union Medical College Hospital from Jan. 2013 to Jan. 2016 were checked for patients' data of epithelial ovarian cancer treated with carboplatin/paclitaxel (every 3 weeks) and patients of cervical cancer treated with concurrent radiochemotherapy using cisplatin (every week). General characters, pathological features, treatment and prognosis of patients were analyzed to determine the severity, symptoms, outcomes and risk factors of HSR...
November 25, 2016: Zhonghua Fu Chan Ke za Zhi
https://www.readbyqxmd.com/read/27856924/prevention-of-carboplatin-induced-hypersensitivity-reactions-in-women-with-ovarian-cancer
#18
Katarzyna J Jerzak, Shaidah Deghan Manshadi, Pamela Ng, Manjula Maganti, Jeanna M McCuaig, Marcus Bulter, Amit Oza, Helen J Mackay
BACKGROUND: Carboplatin-based chemotherapy offers high response rates and improved overall survival for women with epithelial ovarian cancer, but its use is limited by the occurrence of hypersensitivity reactions. To evaluate the efficacy of prophylactic diphenhydramine for hypersensitivity reaction prevention, we reviewed the incidence of hypersensitivity reactions and identified patients at high risk of hypersensitivity reactions. METHODS: Women receiving ≥6 cycles of carboplatin-based chemotherapy for epithelial ovarian cancer were identified from our institutional database at the Princess Margaret Cancer Centre...
November 17, 2016: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/27789084/platinum-desensitization-in-patients-with-carboplatin-hypersensitivity-a-single-institution-retrospective-study
#19
Gary Altwerger, Gregory M Gressel, Diana P English, Wendelin K Nelson, Nina Carusillo, Dan-Arin Silasi, Masoud Azodi, Alessandro Santin, Peter E Schwartz, Elena S Ratner
OBJECTIVES: The carboplatin desensitization (CD) protocol presented here allows patients with either a positive skin test or a prior hypersensitivity reaction (HSR) to safely, rapidly and effectively continue with carboplatin infusions. Newly described factors can identify patients at risk for developing adverse events during CD. METHODS: A retrospective review was performed on patients with gynecologic cancer who underwent CD between 2005 and 2014. The CD protocol uses a four-step dilution process over 3...
January 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/27641482/extended-carboplatin-infusion-does-not-reduce-frequency-of-hypersensitivity-reaction-at-initiation-of-retreatment-in-patients-with-recurrent-platinum-sensitive-ovarian-cancer
#20
Timothy Lax, Don S Dizon, Michael Birrer, Aidan Long, Marcela Del Carmen, Annekathryn Goodman, Carolyn Krasner, Richard T Penson, Whitfield Growdon, Carlos A Camargo, Aleena Banerji
No abstract text is available yet for this article.
September 15, 2016: Journal of Allergy and Clinical Immunology in Practice
keyword
keyword
114338
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"